Lv3
292 积分 2022-08-29 加入
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2小时前
已完结
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
3天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
1个月前
已完结
Prevention and management of amivantamab-induced dermatologic toxicities: a European expert consensus and practical algorithm
1个月前
已完结
MA08.06 Comparison of Asandeutertinib and Osimertinib in EGFR-Mutated NSCLC With Brain Metastases: Interim Analysis of the ESAONA Pivotal Study
2个月前
已关闭
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
3个月前
已完结
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer
5个月前
已完结
QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development
6个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
6个月前
已关闭
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
6个月前
已完结
皖公网安备34019202002308
